{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:21:54Z","timestamp":1788276114571,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10315-4","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T03:59:44Z","timestamp":1769399984000},"source":"Crossref","is-referenced-by-count":1,"title":["Aprepitant increases the antitumor activity of chemotherapy by chemosensitizing breast cancer cells"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6798-4839","authenticated-orcid":false,"given":"Prema","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7587-0025","authenticated-orcid":false,"given":"Marisa","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Zamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2853-8481","authenticated-orcid":false,"given":"Miguel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"10315_CR1","doi-asserted-by":"publisher","unstructured":"Botteri, E., Hjorth, S., Conforti, F., Bagnardi, V., Andreassen B.K., St\u00f8er, N.C., Bhargava, S., Ursin, G., Gandini, S., Sloan, E.K., Chang, A. (2025). Aprepitant use during chemotherapy and association with survival in women with early breast cancer. Journal National Cancer Institute, djaf178. https:\/\/doi.org\/10.1093\/jnci\/djaf178.","DOI":"10.1093\/jnci\/djaf178"},{"issue":"5","key":"10315_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2174\/1389557519666191112152642","volume":"20","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz, M., Rosso, M., & Cove\u00f1as, R. (2020). Triple negative breast cancer: How neurokinin-1 receptor antagonists could be used as a new therapeutic approach. Mini Rev Med Chem, 20(5), 408\u2013417. https:\/\/doi.org\/10.2174\/1389557519666191112152642","journal-title":"Mini Rev Med Chem"},{"key":"10315_CR3","doi-asserted-by":"publisher","unstructured":"Rodriguez, E., Pei, G., Kim, S.T., German, A., Robinson, P. (2021). Substance P antagonism as a novel therapeutic option to enhance efficacy of cisplatin in triple negative breast cancer and protect PC12 cells against cisplatin-induced oxidative stress and apoptosis. Cancers (Basel), 13(15):3871. https:\/\/doi.org\/10.3390\/cancers13153871. Erratum in: (2021) Cancers (Basel), 13(20):5178. https:\/\/doi.org\/10.3390\/cancers13205178","DOI":"10.3390\/cancers13153871"},{"issue":"19","key":"10315_CR4","doi-asserted-by":"publisher","first-page":"9353","DOI":"10.3390\/ijms26199353","volume":"26","author":"M Mu\u00f1oz","year":"2025","unstructured":"Mu\u00f1oz, M., Cove\u00f1as, R., Zuberi, Y., Italia, Z., Hoang, T., Italia, Z., & Robinson, P. (2025). A dual-purpose approach for an anti-emetic nk1r antagonist as a chemosensitizer and cardioprotectant in a preclinical model of triple-negative breast cancer. International Journal of Molecular Science, 26(19), 9353. https:\/\/doi.org\/10.3390\/ijms26199353","journal-title":"International Journal of Molecular Science"},{"issue":"16","key":"10315_CR5","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.2174\/0929867329666220811152602","volume":"30","author":"P Robinson","year":"2023","unstructured":"Robinson, P., Cove\u00f1as, R., & Mu\u00f1oz, M. (2023). Combination therapy of chemotherapy or radiotherapy and the neurokinin-1 receptor antagonist aprepitant: A new antitumor strategy? Current Medicinal Chemistry, 30(16), 1798\u20131812. https:\/\/doi.org\/10.2174\/0929867329666220811152602","journal-title":"Current Medicinal Chemistry"},{"key":"10315_CR6","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3892\/ijo.2014.2565","volume":"45","author":"M Mu\u00f1oz","year":"2014","unstructured":"Mu\u00f1oz, M., Gonz\u00e1lez-Ortega, A., Salinas-Mart\u00edn, M. V., Carranza, A., Garcia-Recio, S., Almendro, V., & Cove\u00f1as, R. (2014). The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. International Journal Oncology, 45, 1658\u201372. https:\/\/doi.org\/10.3892\/ijo.2014.2565","journal-title":"International Journal Oncology"},{"key":"10315_CR7","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3390\/cancers12092682","volume":"12","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz, M., & Cove\u00f1as, R. (2020). The neurokinin-1 receptor antagonist aprepitant: An intelligent bullet against cancer? Cancers, 12, 2682. https:\/\/doi.org\/10.3390\/cancers12092682","journal-title":"Cancers"},{"issue":"8028","key":"10315_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41586-024-07767-5","volume":"633","author":"V Padmanaban","year":"2024","unstructured":"Padmanaban, V., Keller, I., Seltzer, E. S., Ostendorf, B. N., Kerner, Z., & Tavazoie, S. F. (2024). Neuronal substance P drives metastasis through an extracellular RNA-TLR7 axis. Nature, 633(8028), 207\u2013215. https:\/\/doi.org\/10.1038\/s41586-024-07767-5","journal-title":"Nature"},{"key":"10315_CR9","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.23937\/2378-3419\/3\/6\/1071","volume":"3","author":"M Lee","year":"2016","unstructured":"Lee, M., McCloskey, M., & Staples, S. (2016). Long-term use of aprepitant in metastatic breast cancer and reduction in tumor marker CA153 levels. International Journal of Cancer and Clinical Research, 3, 2378\u20133419.","journal-title":"International Journal of Cancer and Clinical Research"},{"issue":"5383","key":"10315_CR10","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","volume":"281","author":"MS Kramer","year":"1998","unstructured":"Kramer, M. S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J. J., Reines, S. A., Liu, G., Snavely, D., Wyatt-Knowles, E., Hale, J. J., Mills, S. G., MacCoss, M., Swain, C. J., Harrison, T., Hill, R. G., Hefti, F., Scolnick, E. M., Cascieri, M. A., \u2026 Rupniak, N. M. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281(5383), 1640\u20135. https:\/\/doi.org\/10.1126\/science.281.5383.1640","journal-title":"Science"},{"issue":"8","key":"10315_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1097\/QAD.0000000000000638","volume":"29","author":"P Tebas","year":"2015","unstructured":"Tebas, P., Spitsin, S., Barrett, J. S., Tuluc, F., Elci, O., Korelitz, J. J., Wagner, W., Winters, A., Kim, D., Catalano, R., Evans, D. L., & Douglas, S.-D. (2015). Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: Phase 1B trial of aprepitant in HIV-1-infected adults. AIDS, 29(8), 931\u20139. https:\/\/doi.org\/10.1097\/QAD.0000000000000638","journal-title":"AIDS"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10315-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10315-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10315-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T03:59:46Z","timestamp":1769399986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10315-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["10315"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10315-4","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"5"}}